Key points are not available for this paper at this time.
During the 2024 Canadian Kidney Cancer Forum (CKCF) held from February 8-10, 2024, in Toronto, Ontario, Canada, a dedicated session convened an expert panel comprising urologic and medical oncologists, other healthcare professionals, and patient advocates.The purpose of this session was to facilitate a discussion on the management of nccRCC and to develop consensus statements based on the best available evidence.These statements are intended to provide practical guidance to healthcare professionals and medical practitioners in their clinical practices.Prior to the session, draft topic statements were generated by two authors (JG, PR) and subjected to review for clarity and completeness by board members of the Kidney Cancer Research Network of Canada (NB, RB, TF, ST, and LW), as detailed in Table 1.These topics spanned diagnostic imaging, pathologic classification, and genetic considerations, as well as treatment options for patients with localized and metastatic nccRCC, with a focus on papillary and chromophobe RCC.
Graham et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: